Spectranetics Corp.
Colorado Springs, Colo.-based Spectranetics Corp., a single-use
medical device manufacturer, has announced its clinical trial plans related to the
treatment of in-stent restenosis in arteries above the knee. Currently, there are
no devices cleared or approved by the FDA to treat in-stent restenosis. The company
has planned to initiate a multicenter randomized trial in the US to compare laser
ablation followed by adjunctive balloon angioplasty with balloon angioplasty alone.
LATEST NEWS
- OIF Project to Address 224G Full Linear Optical Modules
Jun 18, 2024
- Programmable Sensor Provides Fast, High-Quality Imaging of Neural Changes
Jun 18, 2024
- Photon Emission Control for Quantum Applications Sets Precision Record
Jun 17, 2024
- Constantin Häfner Adds Boards Responsibilities at Fraunhofer
Jun 17, 2024
- Vector Photonics Receives Total $3.7M for Laser Commercialization: Week in Brief: 6/14/24
Jun 14, 2024
- Netherlands Partners with New York State on Semiconductors
Jun 14, 2024
- Basler Acquires Stake in Roboception, Adds Logistics, Factory Automation Capabilities
Jun 13, 2024
- Metasurfaces Enable Switch from Edge Detection to IR Imaging
Jun 13, 2024